<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34523063</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1179-2019</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Paediatric drugs</Title>
          <ISOAbbreviation>Paediatr Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.</ArticleTitle>
        <Pagination>
          <StartPage>583</StartPage>
          <EndPage>589</EndPage>
          <MedlinePgn>583-589</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40272-021-00470-2</ELocationID>
        <Abstract>
          <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study was to evaluate the effect of viloxazine extended-release capsules (viloxazine ER; Qelbree™) on executive function deficits (EFDs) in pediatric subjects (6-17 years of age) with attention-deficit/hyperactivity disorder (ADHD).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Data from four phase III placebo-controlled trials of 100-600 mg/day viloxazine ER (6-8 weeks of treatment) were used to evaluate the change from baseline (CFB) in the Conners 3rd Edition Parent Short Form-Executive Function (C3PS-EF) content scale T-score. Subjects were defined as EFD responders if they had C3PS-EF T-score &gt; 70 at baseline and &lt; 65 at end of study. ADHD symptoms were assessed with ADHD Rating Scale 5th Edition (ADHD-RS-5). Subjects were defined as ADHD symptom responders if they had a ≥ 50% reduction in CFB ADHD-RS-5 Total score at Week 6. The number needed to treat (NNT) and Cohen's d effect sizes were estimated for EFD and ADHD symptoms.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1154 subjects were included in the analysis. Statistically significant improvements in EFDs were observed with viloxazine ER versus placebo (p = 0.0002). There were 52.5% of EFD or ADHD symptom responders in the viloxazine ER treatment group and 35.4% in the placebo group (p &lt; 0.0001). The NNT was 5.8. The Cohen's d effect size for EFD and ADHD symptoms was 0.31.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Consistent with the efficacy of viloxazine ER demonstrated in pivotal trials, viloxazine ER significantly reduced EFDs in subjects with ADHD. Moreover, a substantial proportion of subjects treated with viloxazine ER had large improvements in EFDs, ADHD symptoms, or both.</AbstractText>
          <AbstractText Label="CLINICAL TRIAL REGISTRATION NUMBERS" NlmCategory="BACKGROUND">NCT03247530, NCT03247517, NCT03247543, NCT03247556.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Faraone</LastName>
            <ForeName>Stephen V</ForeName>
            <Initials>SV</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomeni</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacometrica, Lieu-dit Longcol, La Fouillade, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hull</LastName>
            <ForeName>Joseph T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Busse</LastName>
            <ForeName>Gregory D</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melyan</LastName>
            <ForeName>Zare</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rubin</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA. anasser@supernus.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT03247530</AccessionNumber>
              <AccessionNumber>NCT03247517</AccessionNumber>
              <AccessionNumber>NCT03247543</AccessionNumber>
              <AccessionNumber>NCT03247556</AccessionNumber>
              <AccessionNumber>NCT03247530</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Paediatr Drugs</MedlineTA>
        <NlmUniqueID>100883685</NlmUniqueID>
        <ISSNLinking>1174-5878</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="Y">Central Nervous System Stimulants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="Y">Viloxazine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>JTH, GDB, ZM, JR, and AN are employees of Supernus Pharmaceuticals, Inc. SVF received income, potential income, travel expenses, continuing education support and/or research support in the past year from Takeda, OnDosis, Tris, Otsuka, Arbor, Ironshore, Rhodes, Akili Interactive Labs, Enzymotec, Sunovion, Supernus, and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health; Oxford University Press: Schizophrenia: The Facts; and Elsevier: ADHD: Non-Pharmacologic Interventions. He is Program Director of www.adhdinadults.com. RG was a paid consultant to Ironshore Pharmaceuticals; Sunovion Pharmaceuticals; Supernus Pharmaceuticals; Teva; Biomedical Science Institutes; Nanomi BVs; Laboratorios Liconsa; Massachusetts General Hospital; UCB; Recordati Rare Diseases; Indivior, Tris Pharma; F. Hoffmann-La Roche.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>7</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34523063</ArticleId>
        <ArticleId IdType="pmc">PMC8563661</ArticleId>
        <ArticleId IdType="doi">10.1007/s40272-021-00470-2</ArticleId>
        <ArticleId IdType="pii">10.1007/s40272-021-00470-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Welsh MC, Pennington BF. Assessing frontal lobe functioning in children: views from developmental psychology. Dev Neuropsychol. 1988;4(3):199–230. doi: 10.1080/87565648809540405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/87565648809540405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoechlin C, Engel RR. Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data. Arch Clin Neuropsychol. 2005;20(6):727–744. doi: 10.1016/j.acn.2005.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.acn.2005.04.005</ArticleId>
            <ArticleId IdType="pubmed">15953706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patros CHG, Tarle SJ, Alderson RM, Lea SE, Arrington EF. Planning deficits in children with attention-deficit/hyperactivity disorder (ADHD): a meta-analytic review of tower task performance. Neuropsychology. 2019;33(3):425–444. doi: 10.1037/neu0000531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/neu0000531</ArticleId>
            <ArticleId IdType="pubmed">30688493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dekkers TJ, Popma A, van Rentergem JAA, Bexkens A, Huizenga HM. Risky decision making in attention-deficit/hyperactivity disorder: a meta-regression analysis. Clin Psychol Rev. 2016;45:1–16. doi: 10.1016/j.cpr.2016.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cpr.2016.03.001</ArticleId>
            <ArticleId IdType="pubmed">26978323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marx I, Hacker T, Yu X, Cortese S, Sonuga-Barke E. ADHD and the choice of small immediate over larger delayed rewards: a comparative meta-analysis of performance on simple choice-delay and temporal discounting paradigms. J Atten Disord. 2021;25(2):171–187. doi: 10.1177/1087054718772138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054718772138</ArticleId>
            <ArticleId IdType="pubmed">29806533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baweja R, Mattison RE, Waxmonsky JG. Impact of attention-deficit hyperactivity disorder on school performance: what are the effects of medication? Paediatr Drugs. 2015;17(6):459–477. doi: 10.1007/s40272-015-0144-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40272-015-0144-2</ArticleId>
            <ArticleId IdType="pubmed">26259966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang S, Yang L, Wang Y, Faraone SV. Shared polygenic risk for ADHD, executive dysfunction and other psychiatric disorders. Transl Psychiatry. 2020;10(1):182. doi: 10.1038/s41398-020-00872-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41398-020-00872-9</ArticleId>
            <ArticleId IdType="pmc">PMC7283259</ArticleId>
            <ArticleId IdType="pubmed">32518222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrath LM, Braaten EB, Doty ND, Willoughby BL, Wilson HK, O'Donnell EH, et al.  Extending the ‘cross-disorder’ relevance of executive functions to dimensional neuropsychiatric traits in youth. J Child Psychol Psychiatry. 2016;57(4):462–471. doi: 10.1111/jcpp.12463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcpp.12463</ArticleId>
            <ArticleId IdType="pmc">PMC4876048</ArticleId>
            <ArticleId IdType="pubmed">26411927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamminga HG, Reneman L, Huizenga HM, Geurts HM. Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis. Psychol Med. 2016;46(9):1791–1807. doi: 10.1017/S0033291716000350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0033291716000350</ArticleId>
            <ArticleId IdType="pubmed">27019103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weisler R, Ginsberg L, Dirks B, Deas P, Adeyi B, Adler LA. Treatment with lisdexamfetamine dimesylate improves self- and informant-rated executive function behaviors and clinician- and informant-rated adhd symptoms in adults: data from a randomized, double-blind, placebo-controlled study. J Atten Disord. 2017;21(14):1198–1207. doi: 10.1177/1087054713518242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054713518242</ArticleId>
            <ArticleId IdType="pubmed">24464328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turgay A, Ginsberg L, Sarkis E, Jain R, Adeyi B, Gao J, et al.  Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. J Child Adolesc Psychopharmacol. 2010;20(6):503–511. doi: 10.1089/cap.2009.0110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2009.0110</ArticleId>
            <ArticleId IdType="pmc">PMC3005278</ArticleId>
            <ArticleId IdType="pubmed">21186969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, et al.  Atomoxetine and executive functioning in adult attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15(4):664–670. doi: 10.1089/cap.2005.15.664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2005.15.664</ArticleId>
            <ArticleId IdType="pubmed">16190797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gau SS, Shang CY. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine. Int J Neuropsychopharmacol. 2010;13(2):243–256. doi: 10.1017/S1461145709990836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1461145709990836</ArticleId>
            <ArticleId IdType="pubmed">19849892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Stralen JPM. A controlled trial of extended-release guanfacine and psychostimulants on executive function and ADHD. J Atten Disord. 2020;24(2):318–325. doi: 10.1177/1087054717751197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054717751197</ArticleId>
            <ArticleId IdType="pubmed">29313415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller U, Clark L, Lam ML, Moore RM, Murphy CL, Richmond NK, et al.  Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology. 2005;182(2):205–213. doi: 10.1007/s00213-005-0078-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-005-0078-4</ArticleId>
            <ArticleId IdType="pubmed">16078088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollins SH, Lopez FA, Vince BD, Turnbow JM, Farrand K, Lyne A, et al.  Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(2):111–120. doi: 10.1089/cap.2010.0064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2010.0064</ArticleId>
            <ArticleId IdType="pubmed">21476931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300. doi: 10.2147/JEP.S256586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JEP.S256586</ArticleId>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al.  A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370–380. doi: 10.1097/JCP.0000000000001404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0000000000001404</ArticleId>
            <ArticleId IdType="pmc">PMC8244935</ArticleId>
            <ArticleId IdType="pubmed">34181360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  A Phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2020.05.021</ArticleId>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8146561</ArticleId>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684–700. doi: 10.1016/j.clinthera.2021.01.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2021.01.027</ArticleId>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparrow EP.  Essentials of conners behavior assessments. Hoboken: Wiley; 2010. </Citation>
        </Reference>
        <Reference>
          <Citation>Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412–419. doi: 10.1111/j.1600-0447.2008.01194.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0447.2008.01194.x</ArticleId>
            <ArticleId IdType="pubmed">18479317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen J.  Statistical power analysis for the behavioral sciences. 2. Routledge; 1988. </Citation>
        </Reference>
        <Reference>
          <Citation>Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160. doi: 10.1136/ebmental-2019-300117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ebmental-2019-300117</ArticleId>
            <ArticleId IdType="pubmed">31563865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T. 2008;33(12):700–711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2730804</ArticleId>
            <ArticleId IdType="pubmed">19750051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, et al.  Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1165–1172. doi: 10.1097/CHI.0b013e3181bc730d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CHI.0b013e3181bc730d</ArticleId>
            <ArticleId IdType="pubmed">19858759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fageera W, Traicu A, Sengupta SM, Fortier ME, Choudhry Z, Labbe A, et al.  Placebo response and its determinants in children with ADHD across multiple observers and settings: a randomized clinical trial. Int J Methods Psychiatr Res. 2018;27(1):e1572. doi: 10.1002/mpr.1572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mpr.1572</ArticleId>
            <ArticleId IdType="pmc">PMC6877247</ArticleId>
            <ArticleId IdType="pubmed">28664541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen A, Plonsky-Toder M, Tirosh E. The short-term placebo response in children with attention-deficit hyperactivity disorder (ADHD) J Child Neurol. 2018;33(5):340–346. doi: 10.1177/0883073818756403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0883073818756403</ArticleId>
            <ArticleId IdType="pubmed">29451082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Monuteaux MC, Doyle AE, Seidman LJ, Wilens TE, Ferrero F, et al.  Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol. 2004;72(5):757–766. doi: 10.1037/0022-006X.72.5.757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/0022-006X.72.5.757</ArticleId>
            <ArticleId IdType="pubmed">15482034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Petty C, Fried R, Fontanella J, Doyle AE, Seidman LJ, et al.  Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(10):1730–1738. doi: 10.1176/ajp.2006.163.10.1730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.2006.163.10.1730</ArticleId>
            <ArticleId IdType="pubmed">17012683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Petty CR, Fried R, Fontanella J, Doyle AE, Seidman LJ, et al.  Can self-reported behavioral scales assess executive function deficits? A controlled study of adults with ADHD. J Nerv Ment Dis. 2007;195(3):240–246. doi: 10.1097/01.nmd.0000243968.06789.73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.nmd.0000243968.06789.73</ArticleId>
            <ArticleId IdType="pubmed">17468684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fried R, Chan J, Feinberg L, Pope A, Woodworth KY, Faraone SV, et al.  Clinical correlates of working memory deficits in youth with and without ADHD: a controlled study. J Clin Exp Neuropsychol. 2016;38(5):487–496. doi: 10.1080/13803395.2015.1127896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13803395.2015.1127896</ArticleId>
            <ArticleId IdType="pmc">PMC4970465</ArticleId>
            <ArticleId IdType="pubmed">26902180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 2013;139(1):81–132. doi: 10.1037/a0028727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/a0028727</ArticleId>
            <ArticleId IdType="pmc">PMC3436964</ArticleId>
            <ArticleId IdType="pubmed">22642228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder HR, Kaiser RH, Warren SL, Heller W. Obsessive-compulsive disorder is associated with broad impairments in executive function: a meta-analysis. Clin Psychol Sci. 2015;3(2):301–330. doi: 10.1177/2167702614534210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2167702614534210</ArticleId>
            <ArticleId IdType="pmc">PMC4351670</ArticleId>
            <ArticleId IdType="pubmed">25755918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Petty CR, Fried R, Black S, Faneuil A, Doyle AE, et al.  Discordance between psychometric testing and questionnaire-based definitions of executive function deficits in individuals with ADHD. J Atten Disord. 2008;12(1):92–102. doi: 10.1177/1087054707305111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054707305111</ArticleId>
            <ArticleId IdType="pubmed">17934182</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34523063</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1179-2019</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Paediatric drugs</Title>
          <ISOAbbreviation>Paediatr Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.</ArticleTitle>
        <Pagination>
          <StartPage>583</StartPage>
          <EndPage>589</EndPage>
          <MedlinePgn>583-589</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40272-021-00470-2</ELocationID>
        <Abstract>
          <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study was to evaluate the effect of viloxazine extended-release capsules (viloxazine ER; Qelbree™) on executive function deficits (EFDs) in pediatric subjects (6-17 years of age) with attention-deficit/hyperactivity disorder (ADHD).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Data from four phase III placebo-controlled trials of 100-600 mg/day viloxazine ER (6-8 weeks of treatment) were used to evaluate the change from baseline (CFB) in the Conners 3rd Edition Parent Short Form-Executive Function (C3PS-EF) content scale T-score. Subjects were defined as EFD responders if they had C3PS-EF T-score &gt; 70 at baseline and &lt; 65 at end of study. ADHD symptoms were assessed with ADHD Rating Scale 5th Edition (ADHD-RS-5). Subjects were defined as ADHD symptom responders if they had a ≥ 50% reduction in CFB ADHD-RS-5 Total score at Week 6. The number needed to treat (NNT) and Cohen's d effect sizes were estimated for EFD and ADHD symptoms.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1154 subjects were included in the analysis. Statistically significant improvements in EFDs were observed with viloxazine ER versus placebo (p = 0.0002). There were 52.5% of EFD or ADHD symptom responders in the viloxazine ER treatment group and 35.4% in the placebo group (p &lt; 0.0001). The NNT was 5.8. The Cohen's d effect size for EFD and ADHD symptoms was 0.31.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Consistent with the efficacy of viloxazine ER demonstrated in pivotal trials, viloxazine ER significantly reduced EFDs in subjects with ADHD. Moreover, a substantial proportion of subjects treated with viloxazine ER had large improvements in EFDs, ADHD symptoms, or both.</AbstractText>
          <AbstractText Label="CLINICAL TRIAL REGISTRATION NUMBERS" NlmCategory="BACKGROUND">NCT03247530, NCT03247517, NCT03247543, NCT03247556.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Faraone</LastName>
            <ForeName>Stephen V</ForeName>
            <Initials>SV</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomeni</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacometrica, Lieu-dit Longcol, La Fouillade, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hull</LastName>
            <ForeName>Joseph T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Busse</LastName>
            <ForeName>Gregory D</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melyan</LastName>
            <ForeName>Zare</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rubin</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Ave, Rockville, MD, 20850, USA. anasser@supernus.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT03247530</AccessionNumber>
              <AccessionNumber>NCT03247517</AccessionNumber>
              <AccessionNumber>NCT03247543</AccessionNumber>
              <AccessionNumber>NCT03247556</AccessionNumber>
              <AccessionNumber>NCT03247530</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Paediatr Drugs</MedlineTA>
        <NlmUniqueID>100883685</NlmUniqueID>
        <ISSNLinking>1174-5878</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="Y">Central Nervous System Stimulants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="Y">Viloxazine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>JTH, GDB, ZM, JR, and AN are employees of Supernus Pharmaceuticals, Inc. SVF received income, potential income, travel expenses, continuing education support and/or research support in the past year from Takeda, OnDosis, Tris, Otsuka, Arbor, Ironshore, Rhodes, Akili Interactive Labs, Enzymotec, Sunovion, Supernus, and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health; Oxford University Press: Schizophrenia: The Facts; and Elsevier: ADHD: Non-Pharmacologic Interventions. He is Program Director of www.adhdinadults.com. RG was a paid consultant to Ironshore Pharmaceuticals; Sunovion Pharmaceuticals; Supernus Pharmaceuticals; Teva; Biomedical Science Institutes; Nanomi BVs; Laboratorios Liconsa; Massachusetts General Hospital; UCB; Recordati Rare Diseases; Indivior, Tris Pharma; F. Hoffmann-La Roche.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>7</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34523063</ArticleId>
        <ArticleId IdType="pmc">PMC8563661</ArticleId>
        <ArticleId IdType="doi">10.1007/s40272-021-00470-2</ArticleId>
        <ArticleId IdType="pii">10.1007/s40272-021-00470-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Welsh MC, Pennington BF. Assessing frontal lobe functioning in children: views from developmental psychology. Dev Neuropsychol. 1988;4(3):199–230. doi: 10.1080/87565648809540405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/87565648809540405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoechlin C, Engel RR. Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data. Arch Clin Neuropsychol. 2005;20(6):727–744. doi: 10.1016/j.acn.2005.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.acn.2005.04.005</ArticleId>
            <ArticleId IdType="pubmed">15953706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patros CHG, Tarle SJ, Alderson RM, Lea SE, Arrington EF. Planning deficits in children with attention-deficit/hyperactivity disorder (ADHD): a meta-analytic review of tower task performance. Neuropsychology. 2019;33(3):425–444. doi: 10.1037/neu0000531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/neu0000531</ArticleId>
            <ArticleId IdType="pubmed">30688493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dekkers TJ, Popma A, van Rentergem JAA, Bexkens A, Huizenga HM. Risky decision making in attention-deficit/hyperactivity disorder: a meta-regression analysis. Clin Psychol Rev. 2016;45:1–16. doi: 10.1016/j.cpr.2016.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cpr.2016.03.001</ArticleId>
            <ArticleId IdType="pubmed">26978323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marx I, Hacker T, Yu X, Cortese S, Sonuga-Barke E. ADHD and the choice of small immediate over larger delayed rewards: a comparative meta-analysis of performance on simple choice-delay and temporal discounting paradigms. J Atten Disord. 2021;25(2):171–187. doi: 10.1177/1087054718772138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054718772138</ArticleId>
            <ArticleId IdType="pubmed">29806533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baweja R, Mattison RE, Waxmonsky JG. Impact of attention-deficit hyperactivity disorder on school performance: what are the effects of medication? Paediatr Drugs. 2015;17(6):459–477. doi: 10.1007/s40272-015-0144-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40272-015-0144-2</ArticleId>
            <ArticleId IdType="pubmed">26259966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang S, Yang L, Wang Y, Faraone SV. Shared polygenic risk for ADHD, executive dysfunction and other psychiatric disorders. Transl Psychiatry. 2020;10(1):182. doi: 10.1038/s41398-020-00872-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41398-020-00872-9</ArticleId>
            <ArticleId IdType="pmc">PMC7283259</ArticleId>
            <ArticleId IdType="pubmed">32518222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrath LM, Braaten EB, Doty ND, Willoughby BL, Wilson HK, O'Donnell EH, et al.  Extending the ‘cross-disorder’ relevance of executive functions to dimensional neuropsychiatric traits in youth. J Child Psychol Psychiatry. 2016;57(4):462–471. doi: 10.1111/jcpp.12463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcpp.12463</ArticleId>
            <ArticleId IdType="pmc">PMC4876048</ArticleId>
            <ArticleId IdType="pubmed">26411927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamminga HG, Reneman L, Huizenga HM, Geurts HM. Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis. Psychol Med. 2016;46(9):1791–1807. doi: 10.1017/S0033291716000350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0033291716000350</ArticleId>
            <ArticleId IdType="pubmed">27019103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weisler R, Ginsberg L, Dirks B, Deas P, Adeyi B, Adler LA. Treatment with lisdexamfetamine dimesylate improves self- and informant-rated executive function behaviors and clinician- and informant-rated adhd symptoms in adults: data from a randomized, double-blind, placebo-controlled study. J Atten Disord. 2017;21(14):1198–1207. doi: 10.1177/1087054713518242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054713518242</ArticleId>
            <ArticleId IdType="pubmed">24464328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turgay A, Ginsberg L, Sarkis E, Jain R, Adeyi B, Gao J, et al.  Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. J Child Adolesc Psychopharmacol. 2010;20(6):503–511. doi: 10.1089/cap.2009.0110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2009.0110</ArticleId>
            <ArticleId IdType="pmc">PMC3005278</ArticleId>
            <ArticleId IdType="pubmed">21186969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, et al.  Atomoxetine and executive functioning in adult attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15(4):664–670. doi: 10.1089/cap.2005.15.664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2005.15.664</ArticleId>
            <ArticleId IdType="pubmed">16190797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gau SS, Shang CY. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine. Int J Neuropsychopharmacol. 2010;13(2):243–256. doi: 10.1017/S1461145709990836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1461145709990836</ArticleId>
            <ArticleId IdType="pubmed">19849892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Stralen JPM. A controlled trial of extended-release guanfacine and psychostimulants on executive function and ADHD. J Atten Disord. 2020;24(2):318–325. doi: 10.1177/1087054717751197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054717751197</ArticleId>
            <ArticleId IdType="pubmed">29313415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller U, Clark L, Lam ML, Moore RM, Murphy CL, Richmond NK, et al.  Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology. 2005;182(2):205–213. doi: 10.1007/s00213-005-0078-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-005-0078-4</ArticleId>
            <ArticleId IdType="pubmed">16078088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollins SH, Lopez FA, Vince BD, Turnbow JM, Farrand K, Lyne A, et al.  Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(2):111–120. doi: 10.1089/cap.2010.0064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2010.0064</ArticleId>
            <ArticleId IdType="pubmed">21476931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300. doi: 10.2147/JEP.S256586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JEP.S256586</ArticleId>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al.  A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370–380. doi: 10.1097/JCP.0000000000001404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0000000000001404</ArticleId>
            <ArticleId IdType="pmc">PMC8244935</ArticleId>
            <ArticleId IdType="pubmed">34181360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  A Phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2020.05.021</ArticleId>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8146561</ArticleId>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684–700. doi: 10.1016/j.clinthera.2021.01.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2021.01.027</ArticleId>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparrow EP.  Essentials of conners behavior assessments. Hoboken: Wiley; 2010. </Citation>
        </Reference>
        <Reference>
          <Citation>Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412–419. doi: 10.1111/j.1600-0447.2008.01194.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0447.2008.01194.x</ArticleId>
            <ArticleId IdType="pubmed">18479317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen J.  Statistical power analysis for the behavioral sciences. 2. Routledge; 1988. </Citation>
        </Reference>
        <Reference>
          <Citation>Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160. doi: 10.1136/ebmental-2019-300117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ebmental-2019-300117</ArticleId>
            <ArticleId IdType="pubmed">31563865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T. 2008;33(12):700–711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2730804</ArticleId>
            <ArticleId IdType="pubmed">19750051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, et al.  Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1165–1172. doi: 10.1097/CHI.0b013e3181bc730d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CHI.0b013e3181bc730d</ArticleId>
            <ArticleId IdType="pubmed">19858759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fageera W, Traicu A, Sengupta SM, Fortier ME, Choudhry Z, Labbe A, et al.  Placebo response and its determinants in children with ADHD across multiple observers and settings: a randomized clinical trial. Int J Methods Psychiatr Res. 2018;27(1):e1572. doi: 10.1002/mpr.1572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mpr.1572</ArticleId>
            <ArticleId IdType="pmc">PMC6877247</ArticleId>
            <ArticleId IdType="pubmed">28664541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen A, Plonsky-Toder M, Tirosh E. The short-term placebo response in children with attention-deficit hyperactivity disorder (ADHD) J Child Neurol. 2018;33(5):340–346. doi: 10.1177/0883073818756403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0883073818756403</ArticleId>
            <ArticleId IdType="pubmed">29451082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Monuteaux MC, Doyle AE, Seidman LJ, Wilens TE, Ferrero F, et al.  Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol. 2004;72(5):757–766. doi: 10.1037/0022-006X.72.5.757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/0022-006X.72.5.757</ArticleId>
            <ArticleId IdType="pubmed">15482034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Petty C, Fried R, Fontanella J, Doyle AE, Seidman LJ, et al.  Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(10):1730–1738. doi: 10.1176/ajp.2006.163.10.1730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.2006.163.10.1730</ArticleId>
            <ArticleId IdType="pubmed">17012683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Petty CR, Fried R, Fontanella J, Doyle AE, Seidman LJ, et al.  Can self-reported behavioral scales assess executive function deficits? A controlled study of adults with ADHD. J Nerv Ment Dis. 2007;195(3):240–246. doi: 10.1097/01.nmd.0000243968.06789.73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.nmd.0000243968.06789.73</ArticleId>
            <ArticleId IdType="pubmed">17468684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fried R, Chan J, Feinberg L, Pope A, Woodworth KY, Faraone SV, et al.  Clinical correlates of working memory deficits in youth with and without ADHD: a controlled study. J Clin Exp Neuropsychol. 2016;38(5):487–496. doi: 10.1080/13803395.2015.1127896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13803395.2015.1127896</ArticleId>
            <ArticleId IdType="pmc">PMC4970465</ArticleId>
            <ArticleId IdType="pubmed">26902180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 2013;139(1):81–132. doi: 10.1037/a0028727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/a0028727</ArticleId>
            <ArticleId IdType="pmc">PMC3436964</ArticleId>
            <ArticleId IdType="pubmed">22642228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder HR, Kaiser RH, Warren SL, Heller W. Obsessive-compulsive disorder is associated with broad impairments in executive function: a meta-analysis. Clin Psychol Sci. 2015;3(2):301–330. doi: 10.1177/2167702614534210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2167702614534210</ArticleId>
            <ArticleId IdType="pmc">PMC4351670</ArticleId>
            <ArticleId IdType="pubmed">25755918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Petty CR, Fried R, Black S, Faneuil A, Doyle AE, et al.  Discordance between psychometric testing and questionnaire-based definitions of executive function deficits in individuals with ADHD. J Atten Disord. 2008;12(1):92–102. doi: 10.1177/1087054707305111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054707305111</ArticleId>
            <ArticleId IdType="pubmed">17934182</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
